Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01042704 · ClinicalTrials.gov registry record · Phase 1
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
A Phase 1 study, sponsored by Robert Redner, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT01042704 is a Phase 1 study that has completed, run by Robert Redner, MD. The registered enrollment target is 29 participants.
The verdict
NCT01042704, a Phase 1 study, has completed, sponsored by Robert Redner, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to see if the combination of bendamustine, lenalidomide and dexamethasone will help people with multiple myeloma that has returned after standard treatment or has been resistant to other treatments.
Interventions
- DRUG Aspirin
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Bendamustine
- DRUG Prophylaxis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2008-02 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01042704
The ClinicalTrials.gov registry entry for NCT01042704 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Robert Redner, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Aspirin is the first listed.
NCT01042704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01042704 about?
NCT01042704 is a clinical study titled "Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma". The purpose of this study is to see if the combination of bendamustine, lenalidomide and dexamethasone will help people with multiple myeloma that has returned after standard treatment or has been resistant to other treatments.
What is the current status of trial NCT01042704?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2008-02. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01042704?
The interventions under investigation include: Aspirin (DRUG), Dexamethasone (DRUG), Lenalidomide (DRUG), Bendamustine (DRUG), Prophylaxis (DRUG).
Who is sponsoring clinical trial NCT01042704?
This trial is sponsored by Robert Redner, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.